• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

Briefly.net

media intelligence

  • Sponsored Post
  • Make a Contribution
  • Market Forecasts
  • Domain Marketplace
  • About
  • Contact

Covid-busting Nasal Spray Begins UK Trials January 11th

January 10, 2021 By admin Leave a Comment

The first UK clinical trials of a nasal spray proven to kill 99.9% of the coronavirus that causes Covid-19 will begin on January 11th at Ashford and St Peter’s Hospitals NHS Foundation Trust, in Surrey.

SaNOtize Nitric Oxide Nasal Spray (NONS) kills 99.9% of coronavirus in lab tests
Nasal spray blocks viral entry into the body, destroys virus and prevents it from multiplying
Nitric oxide blocks ACE-2 receptor essential for the virus to infect cells, destroys Covid mutant variations
Clinical trials already underway in Canada and approved to start in the USA
London University professor conducting trial hopes for ‘significant advance in our therapeutic armoury against this devastating disease’

The SaNOtize Nitric Oxide Nasal Spray (NONS) is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs.

The treatment, developed by SaNOtize Research and Development Corp. based in Vancouver, Canada, proved 99.9% effective in killing the coronavirus in independent lab tests at Utah State University’s Antiviral Research Institute. Additional studies in rodents with COVID-19 infection showed over 95% reduction within the first day after infection. It is currently undergoing Phase II clinical trials throughout Canada approved by Health Canada, and in other countries.

The SaNOtize treatment is based on nitric oxide, a natural nanomolecule produced by the human body with proven anti-microbial properties shown to have a direct effect on SARS-CoV-2, the virus that causes Covid-19. The treatment can be delivered by nasal spray, throat gargle or nasal lavage.

Lab tests on the SaNOtize treatment at Utah State University’s Antiviral Research Institute confirmed that the company’s Nitric Oxide Releasing Solution inactivated more than 99.9% of SARs-CoV-2, the virus that causes Covid-19, within two minutes.

Rodent studies performed at Colorado State University showed an average of over 95% reduction in SARS-CoV-2 viral load tested on the day following infection with half the rodents having no detectable virus at all. This was following inoculation with the virus and two treatments of SaNOtize’s nasal spray.

“Any intervention for treating coronavirus – the virus responsible for Covid-19 – is to be welcomed. The fact that a relatively easy and simple nasal spray could be an effective treatment is welcome news and offers a significant advance in our therapeutic armoury against this devastating disease. Ashford and St Peters Hospitals NHS Foundation Trust is proud to be at the forefront of trialling this intervention,” said Pankaj Sharma MD PhD FRCP, Professor of Neurology and Director of the Institute of Cardiovascular Research at Royal Holloway, University of London.

The importance of nitric oxide within the human body and its healing properties was first discovered by Prof Ferid Murad of Stanford University, among others, for which he shared the Nobel Prize in Medicine in 1998. Prof Murad is a member of the board of SaNOtize.

“Nitric oxide is an incredibly versatile molecule that regulates almost everything in our body,” Dr Murad said. “When used therapeutically, it has a well-documented safety profile and is demonstrated to be effective against a wide variety of viruses, bacteria and fungi. I’m excited to be working with the SaNOtize team and believe that they have a safe technology that could be effective in treating infections, including Covid-19.”

“The SaNOtize nasal spray provides a barrier. It contains nitric oxide which prevents and treats early infection by destroying the virus and impeding viral replication within the cells in the nose. In addition, nitric oxide has been shown to block the ACE-2 receptor essential for the virus to infect our cells. That is what makes our product unique and enables it to stand alone from any other nasal approach,” said Dr Chris Miller, chief science officer and co-founder of SaNOtize.

“It’s a safe technology that could be effective in treating infections, including Covid-19,” Dr Miller said. “Everybody just thinks you get the virus, and it gets into your lungs, and you die, but it’s a progression. First you get exposed to it, and the virus tries to attach to the cells in your nose, and it takes a while to incubate, and multiply in nasal cells for a few days and then the virus will shed into your lungs.”

“What we envision is cleansing the upper respiratory area at various points in the day. In the morning when you get up, where the virus has shed and started collecting in the back of your upper airway, first spray of the day, and then you go out into the day, and you can’t always control social distancing as we end lockdown, and so we have nasal sprays throughout the day. At the end of the day you come home and you basically rinse your nose and your nasopharynx, so that will clean your nose, your sinuses, and the back of your throat where these viruses initially reside,” Dr Miller said.

Rob Wilson, a former British government minister who represents SaNOtize in the UK and EU, is overseeing the trial.

“If, as we expect, the current Phase II results in Canada confirm the very encouraging results received from the Antiviral Research Institute and ongoing studies at Colorado State University SaNOtize will be seeking emergency approval in Canada to proceed directly to Phase IV introduction of the product to the market as part of the continuing global fight against this deadly pandemic,” said Wilson.

“The vaccination programme is essential, but it will also take time to distribute to the general public. Mutant strains may develop, requiring changes to the vaccine. It is not known how long the immunological protection will last.It is also unclear if the vaccines will prevent vaccinated people from becoming infected and potentially transmit the virus to other non-protected individuals.

For these reasons it is important to explore and deliver simple, safe and inexpensive therapeutic product solutions over the counter in the UK and EU as soon as possible, which is why I am getting these UK trials, the first in Europe, underway very shortly. The nasal spray not only can block entry of the virus, but the active ingredient nitric oxide actually kills the virus and prevents it from multiplying. If successful, people in Britain and Europe could have an effective, safe and accessible treatment within months that they can use daily to kill the coronavirus and stop it spreading,” Wilson said.

“This simple treatment will assist us in resuming something approaching normal social life, work and travel with some confidence that even if we inhale the virus, we can both protect against it and destroy it by applying the SaNOtize solution on a regular basis,” Wilson said.

“The SaNOtize treatment should be thought of as an effective treatment for the upper airways, similar to when people use hand sanitizers to clean their hands on the outside of the body. When people are potentially exposed, they will spray to cleanse their upper airways and kill the virus, before it can cause serious illness,” Wilson said.

Research published in Nature confirms that the nose is the primary infection area especially in the early period of the infection. Hospital trials with nitric oxide are underway in the US and Europe with seriously ill coronavirus patients inhaling the gas to kill the virus in their lungs and prevent progression to severe infection. SaNOtize’s solution can be applied away from a hospital setting. It is easy to use, inexpensive and safe.

The company’s strategy is to use the Nitric Oxide spray as a multi-stage defence against infection and to provide an effective treatment for mild and moderate cases with the goal of preventing severe inflammatory response and infection of the lungs.

Scientists believe the coronavirus is transmitted via airborne droplets to the mucous membranes in the nose, where it is replicated during a three-day incubation period, damaging the nasal mucosa cells, and is then carried in nasal secretions to the lower respiratory tract, leading to the danger of fatal viral pneumonia.

Filed Under: Brief Tagged With: covid19

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Market Analysis

Crash course will teach you the basics so you can code APIs quickly
The future belongs to Ethereum app store
Event Calendar
The future belongs to AIML-powered ecommerce
Automation is the future of retail market
Luxury-Home Sales Sink 18%, the Biggest Decline Since the Start of the Pandemic
When synthetic biology will disrupt an industry?

Market Research Media

PandemicBurnout.com: Pandemic Burnout
The current market value for AR/VR/MR is around $30.7B, and the worldwide market may rise to $300B by 2024
GenZnomads.com: Gen Z Nomads Want to Work from Home
InfluenceMgmt.com (Influence Management): How to get others to adopt your recommendation
FashionInfluential.com (Fashion Influential): Fashion Industry Trends
VisualMediaMarket.com: Visual Media Market
MktForecast.com: Market Forecast Methodology

Secondary Sidebar

Technologies

Samsung Introduces the Industry’s First 5nm Processor Powering the Next Generation of Wearables
Facing disruption: how companies in every industry can move confidently into the future
MulticoreWare Inc.’s VVC Consortium Gains Momentum
The energy in nuclear waste could power the U.S. for 100 years
Broadcom to Acquire VMware for Approximately $61 Billion in Cash and Stock

Calendarial

Copenhagen Democracy Summit 2022, June 9-10, 2022
Microsoft Research Summit, October 19-21, 2021
2022 Safety and Security Summit @ Esri UC , the world’s largest GIS event dedicated to public safety, emergency management, and national security, July 9-12, 2022, San Diego
World Economic Forum: Annual Meeting will take place 22-26 May 2022 in Davos
Horizon 2022 Conference: The virtual event is set for February 15 in EMEA and North America, and on February 17 for APAC

Footer

Recent Posts

  • Companies That Prioritize Suppliers and Procurement Can Weather Today’s Crises and Win Tomorrow’s Postpandemic Opportunities, Says New Book from BCG
  • How to hire a problem solver?
  • Why do businesses fail?
  • Arm is gaining traction in server market
  • How to engage your employees
  • 95% of executives believe metaverse will positively impact their industry
  • Statement by U.S. Conference of Mayors on SCOTUS Decision to End Women’s Right to Safe, Legal, Accessible Abortion
  • How many consumers expect to purchase more online in the next six months? One in three
  • API Coding Digest, June 22, 2022
  • How business can bridge the skills gap?

RSS VPNW

  • As a technical writer, it’s pretty common to do the thing you’re documenting
  • Most Platforms Fail
  • Adaptability Paradox
  • Fear holds back innovation efforts
  • Technology Digest

RSS Pixel Effect

  • What are digital nomad villages?
  • Neither of these images are photographs
  • Peppers and Eggplants, the Quintessential Ingredients of Sicilian Cuisine
  • Words matter, pixels enhance words
  • Literary tourism has become a mass pursuit

RSS S3H

  • No more Côte d’Azur for Russian oligarchs
  • MKTG DEV 2022
  • WiFi as a Service
  • Small Refineries Respond to U.S. EPA Decision on 2021 and 2022 Blending Mandates
  • Sony: The DSLR is dead, long live the smartphone!

RSS OPINT

  • Macro-Eyes Wins the 2022 xTeachsearch6 Army technology innovation competition
  • For the next 5 years Macron will be scratching around for the votes he needs to get anything done
  • A long and protracted conflict between Western democracies and authoritarian systems
  • ICE Semiconductor Index Selected as Benchmark for Mega International’s New Taiwan-Listed ETF
  • Production as a service (PaaS) is a huge opportunity

Copyright © 2020 Briefly.net

Technologies, Market Analysis & Market Research Reports

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT